IFI-M · CAK Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-02126 // MULTI-AXIS · IFI-M

CAK Tri-Axis Dominant-Primary Series I-AG

Mentha × piperita

Peppermint

Tier ICAK Tri-Axis Dominant-Primary Series

Target Trait

1.1×

fold-change

Cooling-dominant tri-axis A+K modulated fold-change

Technical Specifications

SKU

SS-F-M3-02126

Genomic Edits

6

GC Content

44.7%

Construct Length

4,311 bp

Promoter System

Tissue-specific 2A11

Expression System

Agrobacterium-mediated T-DNA

Host Strain

EHA105

Receptor Target

TRPM8 + Polyphenol-astringency axis + CaSR

IFI Score

110

Pathway Edits

  • TRPM8 pathway primary gene cluster for cooling (IFI-C) tri-axis component
  • Polyphenol-astringency axis pathway primary gene cluster for astringency (IFI-A) tri-axis component
  • CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent CAK pathway operation
  • Cross-pathway regulatory circuit for cooling-dominant CAK triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPM8, Polyphenol-astringency axis, and CaSR pathways simultaneously engineeredCooling-dominant tri-axis expression strategy (CAK) with cross-pathway flux managementT-DNA binary vector 2A11 for stable genomic integration of multi-axis construct stack

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier I CAK triple-axis construct for advanced multi-modal sensory architecture combining cooling, astringency, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$299 · Tier I License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Multi-Axis · IFI-MAll Modalities